What changed for Psoriasis
A plain English summary of what recently moved in the public data Voxsanity tracks for Psoriasis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 4 to 3 (-1)
- Trials recruiting worldwide 122 to 132 (+10)
- Late-stage (Phase 3) trials 18 to 19 (+1)
- Trials on record 1,694 to 1,785 (+91)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Psoriasis in July 2026. Voxsanity tracks 18 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 246 trials tracked for Psoriasis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT06095102 · results posted 25 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06095102) enrolled 311 people with plaque psoriasis — 103 received a placebo (an inactive treatment) and 208 received a pill called JNJ-77242113 at a dose of 200 mg. By the end of the study, 93 people in the placebo group and 200 in the JNJ-77242113 group had completed the trial. The trial was measuring how participants' psoriasis responded after 16 weeks, using several scoring systems where doctors rated the severity of skin plaques, scalp involvement, genital skin involvement, and hand and foot involvement. The reported...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06220604 · results posted 25 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 731 adults with plaque psoriasis across three groups: 82 people received a placebo (dummy treatment) for the first 16 weeks before switching to the study drug JNJ-77242113 (200 mg); 322 people received JNJ-77242113 (200 mg) from the start; and 327 people received a comparator drug called deucravacitinib (6 mg). The trial was primarily measuring how many participants' skin cleared or nearly cleared by week 16, using two standard psoriasis scoring tools — one rated by a doctor's overall assessment of the skin (IGA), and...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06143878 · results posted 25 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 774 adults with plaque psoriasis across three groups: 156 people received a placebo (inactive treatment) for the first 16 weeks before switching to the study drug JNJ-77242113 200 mg; 311 people received JNJ-77242113 200 mg from the start; and 307 people received an already-approved medicine called deucravacitinib 6 mg. The trial was primarily measuring how many participants showed a meaningful improvement in their skin at 16 weeks, using two standard psoriasis scoring tools — one rated by a doctor (the IGA scale) and...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05272150 · results posted 24 June 2026
According to the results reported on ClinicalTrials.gov, this trial looked at guselkumab (a 100 mg injection) compared to a placebo (an inactive treatment) in people with psoriasis. The trial was split into two groups: Cohort A focused on general plaque psoriasis across the body, and Cohort B focused on scalp psoriasis. In total, 211 people started the trial — 103 in Cohort A and 108 in Cohort B. Some participants who started on placebo later switched to guselkumab during the study. The main things being measured at the 16-week mark were how many participants had their skin condition rated as...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01872546 · results posted 24 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 18 adults who received a medication called adalimumab. All 18 participants completed the study — none dropped out. The trial was looking at two things after 4 weeks of treatment: changes in a skin disease severity score called the PASI (Psoriasis Area and Severity Index, a standard way of measuring how much of the body is affected by psoriasis and how severe it looks), and changes in a quality-of-life score called the DLQI (Dermatology Life Quality Index, a questionnaire about how a skin condition affects day-to-day l...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06357221 · results posted 9 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06357221) enrolled 46 people who had psoriasis, all of whom used a skincare product as the single treatment being tested. Of the 46 who started, 41 completed the trial and 5 did not finish. The trial tracked several things over time: how much body surface area was affected by psoriasis (using a "handprint" method, where one handprint equals roughly 1% of the body's skin), how severe a specific target patch of psoriasis looked (scored on a 0–24 scale), how a doctor rated the overall psoriasis severity (scored 0–5), how scal...
-
NCT05364554 · results posted 1 June 2026
According to the results reported on ClinicalTrials.gov, this trial involved 227 people with psoriasis across six groups, each receiving a different dose or dosing schedule of an investigational tablet called JNJ-77242113, or a placebo that was later switched to the active treatment. The groups ranged in size from 35 to 40 participants at the start, and between 27 and 35 in each group completed the study. The trial measured how participants' psoriasis changed after 36 weeks of a long-term extension period, using several standardised scoring tools that assess the severity and extent of skin pla...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06095115 · results posted 1 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 684 participants with plaque psoriasis — 228 in the placebo group and 456 in the JNJ-77242113 200 mg group. The trial was measuring how participants' skin responded over 16 weeks using two main scoring tools: the IGA (Investigator's Global Assessment), which rates overall skin clearance on a scale from 0 (completely clear) to 4 (severe), and the PASI (Psoriasis Area and Severity Index), which scores the extent and severity of psoriasis across the body on a scale of 0 to 72. The trial also tracked responses at earlier...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05357755 · results posted 5 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 89 people with psoriasis across three groups: 24 received a placebo (a dummy pill with no active ingredient), 31 received a lower dose of the investigational pill JNJ-77242113 (10 mg once daily), and 34 received a higher dose (50 mg once daily). The trial ran for 16 weeks and was primarily measuring how many participants saw their psoriasis severity score — called the PASI score, a standardised 0–72 scale where higher numbers mean more severe psoriasis — improve by at least 75% from where it started. The reported dat...
-
NCT06042920 · results posted 17 April 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called deucravacitinib (also referred to in the trial as BMS-986165) in people with two specific types of psoriasis — psoriasis affecting the palms and soles of the feet (called palmoplantar psoriasis), and psoriasis affecting the genital area. The trial had two phases: a placebo-controlled phase (where some participants received the active medicine and others received a dummy treatment with no active ingredient) and an active treatment phase (where all participants received the medicine). In the placebo-c...
-
NCT05366855 · results posted 27 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05366855) was a follow-on maintenance study involving 42 participants in total across eight different groups. People who had taken part in an earlier trial of imsidolimab (a medicine being investigated for Generalised Pustular Psoriasis, or GPP — a rare and serious skin condition) were placed into groups depending on how they had responded previously and what treatment they received in this study. The study was measuring how often unwanted health events (called adverse events) occurred, and tracking whether participants' s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05352893 · results posted 17 March 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called imsidolimab for people with a serious skin condition called generalised pustular psoriasis (GPP), which causes widespread painful pus-filled spots. Forty-five people took part in total — 15 received a higher dose of imsidolimab (750 mg), 15 received a lower dose (300 mg), and 15 received a placebo (a dummy treatment with no active medicine). The main thing the trial was measuring was how many people's skin was rated as "clear" or "almost clear" by their doctor using a standard 5-point scoring tool,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06011733 · results posted 20 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06011733) enrolled 133 adults with moderate to severe psoriasis. Participants were split into two groups: 33 people who started on a placebo (an inactive treatment) before switching to the medicine bimekizumab, and 100 people who received bimekizumab from the start. The trial was measuring how much psoriasis improved over time using two main scoring tools — a detailed skin assessment called the PASI score (which rates redness, thickness, and scaling across the body on a scale where 0 means no disease and 72 means the most...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04246372 · results posted 11 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 47 participants who were already receiving tofacitinib (a tablet medicine) as part of their usual care for one of five immune-related skin conditions: alopecia areata (patchy hair loss), atopic dermatitis (eczema), vitiligo, psoriasis, or hidradenitis suppurativa. Forty-two of the 47 participants completed the study. The trial was primarily measuring two things over 16 weeks: any serious unwanted events that were definitely caused by tofacitinib, and changes in a molecular measure called an "Interferon Score" — a labo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04936308 · results posted 8 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04936308) enrolled 453 people in total across three groups: 150 who started on a placebo and later switched to guselkumab 100 mg, 152 who received guselkumab 100 mg every 8 weeks, and 151 who received guselkumab 100 mg every 4 weeks. The trial was measuring outcomes in people with psoriatic arthritis — a condition involving joint inflammation alongside the skin condition psoriasis. The main thing the trial was tracking was whether participants' joint symptoms improved by at least 20% (a standard measure called an ACR 20 re...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05730725 · results posted 25 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 109 people in total across four groups — a placebo group (28 people) and three treatment groups (27 people each). The trial was studying a treatment for moderate-to-severe psoriasis, a skin condition. The main things being measured were how much participants' psoriasis skin scores improved after 12 weeks, and information about unwanted health events that occurred during the trial. Most participants completed the study: 24 out of 28 in the placebo group, and 25–26 out of 27 in each treatment group. The reported data s...
-
NCT04271540 · results posted 25 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 36 people who had psoriasis (a skin condition) and were treated with a medicine called tildrakizumab. The trial was measuring how the drug affected blood flow in the heart's arteries — specifically something called "coronary flow reserve" (CFR), which is a way of measuring how well the heart's blood vessels can increase blood flow when the body needs more. Thirty participants completed the study, and six did not finish. There was only one group in this trial — everyone received the treatment, so there was no compariso...
-
NCT06176768 · results posted 15 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06176768) enrolled 33 people with psoriasis — 16 received the investigational medicine LY3972406 and 17 received a placebo (a dummy treatment with no active ingredient). The trial was primarily measuring how many participants achieved at least a 75% reduction in their psoriasis severity score (called PASI-75), a standard way of tracking how much psoriasis improves. The trial was terminated early, with only 3 participants in the LY3972406 group and 4 in the placebo group completing the full study period. The reported data...
-
NCT05811234 · results posted 24 September 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 291 adults who used a cream called CAL/BDP PAD Cream — a combination topical treatment applied to the scalp — for scalp psoriasis. Of those who started, 265 completed the trial. The study measured how satisfied participants were with the medication (using a questionnaire called TSQM-9), how the condition affected their quality of life and itch levels (using tools called Scalpdex and WI-NRS), and how many participants' scalps were rated as "clear" or "almost clear" by a doctor (called Scalp-PGA treatment success). The...
-
NCT03897075 · results posted 6 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 99 people in total — 48 received a placebo (a dummy treatment with no active ingredient) and 51 received a medicine called tildrakizumab at a dose of 100 mg. The trial was looking at nail psoriasis, a condition where psoriasis affects the fingernails or toenails. The main thing researchers were measuring was how many participants saw their nail psoriasis score (using a scale called the mNAPSI) improve by at least 75% after 28 weeks of treatment. By the end of the study, 35 people in the placebo group and 43 in the til...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04717466 · results posted 5 June 2025
According to the results reported on ClinicalTrials.gov, this trial involved 20 people in total — 10 with psoriasis and 10 without (referred to as the healthy group). All 20 participants completed the study. The trial was looking at whether there were any differences in brain structure and brain activity between the two groups, and whether these changed over a four-week period. For the psoriasis group, researchers also tracked itch, pain, and skin severity scores, as well as overall wellbeing for both groups. The reported data shows the following changes from the start of the study to week fo...
-
NCT05195814 · results posted 30 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05195814) enrolled 141 people with psoriatic arthritis — 66 in a group taking tofacitinib on its own, and 75 in a group taking tofacitinib together with another medicine called OSM (a combination therapy). All 141 participants completed the study. The trial was measuring several things over six months: how many joints were tender or swollen, whether participants reached a state of low or minimal disease activity, how much skin was affected by psoriasis, and whether a specific type of joint-area inflammation (called enthesi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03451851 · results posted 28 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03451851) looked at plaque psoriasis in children and adolescents. In the first part of the trial (weeks 0 to 16), participants were split into three groups: 25 received a placebo (an inactive treatment), 41 received guselkumab, and 26 received etanercept. A separate second part of the trial also enrolled 28 additional participants who received guselkumab. The trial measured how much participants' psoriasis improved using two main tools: a doctor's overall rating of skin clearance (called the IGA, scored from 0 = clear skin...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04908514 · results posted 11 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04908514) looked at a treatment called ADX-629 for psoriasis. Ten people started the study, seven completed it, and three did not finish. The trial was mainly measuring changes in psoriasis severity using a standard scoring tool called the Psoriasis Area and Severity Index (PASI), which runs from 0 (no psoriasis) to 72 (maximum severity). A second scoring tool, the Investigator's Global Assessment (IGA), was also used — this runs from 0 (clear skin) to 4 (severe). The reported data shows that, for the PASI score, the aver...
-
NCT03047395 · results posted 11 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03047395) enrolled 2,170 people who were all given risankizumab 150 mg. Of those who started, 1,601 completed the study and 569 did not finish. The trial's main focus was on tracking and recording adverse events — that is, any unwanted or unexpected medical occurrences that happened during the study, whether or not they were thought to be related to the medication. The reported data shows two categories of adverse events were counted. A serious adverse event was defined as something that caused death, was life-threatening...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03598790 · results posted 6 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03598790) looked at a medicine called bimekizumab (BKZ) in people with different forms of psoriasis — a skin condition. Participants were placed into groups depending on their type of psoriasis and how often they received the medicine (either every four weeks or every eight weeks). In total, more than 1,300 people took part across the main treatment period and a follow-up extension phase. The trial measured how often unwanted health events (called adverse events) occurred, as well as how much participants' skin improved ov...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03706209 · results posted 22 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03706209) looked at a medicine called MP1032 for people with psoriasis, a skin condition. A total of 155 people started the trial across three groups: 52 people took a lower dose of MP1032 (150 mg twice daily), 48 took a higher dose (300 mg twice daily), and 55 took a placebo (a dummy treatment with no active ingredient). By the end of the study, 36, 39, and 39 people respectively had completed the trial in each group. The trial measured two main things after 12 weeks: how many people's psoriasis skin scores improved by at...
-
NCT03726489 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03726489) enrolled 390 people in an office-based light therapy (phototherapy) group and 393 people in a home-based light therapy group — 783 participants in total. The trial was studying phototherapy for psoriasis, comparing treatment received at a clinic versus treatment done at home. It measured two main things: how many participants' skin was rated as "clear" or "almost clear" by a doctor (using a scoring tool called the Physician Global Assessment, or PGA), and how many participants reported that psoriasis had little o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02984020 · results posted 27 August 2024
According to the results reported on ClinicalTrials.gov, this was a post-marketing surveillance study of Xeljanz (tofacitinib) — meaning it was designed to track what happened to patients already using the medicine in routine clinical practice, rather than testing it against a comparison group. A total of 1,041 people were enrolled, 1,009 of them completed the study, and 32 did not finish. The study was focused entirely on monitoring and recording any medical events that occurred while participants were taking Xeljanz. The reported data shows that out of 1,041 participants, 261 experienced at...
-
NCT00563524 · results posted 23 August 2024
According to the results reported on ClinicalTrials.gov, this trial tested an investigational drug called ILV-094 across six groups of participants. A total of 76 people took part — split across four ILV-094 dose groups (given either by injection under the skin or directly into a vein) and two placebo groups (one for each delivery method). The trial was primarily focused on monitoring participants for any medical events or notable changes in their heart readings, vital signs (such as blood pressure and heart rate), and blood and urine test results during and after treatment, up to around 18 we...
See all 246 reported results for Psoriasis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, psoriasis is receiving a substantial level of public research investment from the United States, and that investment has been rising year on year. This is an encouraging sign for patients, as growing funding generally means more researchers are actively working to better understand the condition and explore new approaches. While funding alone does not guarantee treat...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.